FDA approves Votrient for RCC

FDA approved Votrient pazopanib from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) late Monday to treat advanced renal cell carcinoma. Earlier this month, the agency's Oncologic Drugs Advisory Committee vot...